𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate Cancer

✍ Scribed by Akinobu Hamada; Romano Danesi; Douglas K. Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L. Dahut; William D. Figg

Book ID
116947763
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
120 KB
Volume
70
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Androgen receptor polymorphisms: Associa
Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
✍ Stephen M. Edwards; Mike D. Badzioch; Ralph Minter; Rifat Hamoudi; Nadine Collin πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 179 KB πŸ‘ 1 views

Several reports have suggested that one or both of the trinucleotide repeat polymorphisms in the human androgen receptor (hAR) gene, (CAG) n coding for polyglutamine and (GGC) n coding for polyglycine, may be associated with prostate cancer risk; but no study has investigated their association with

A polymorphism in the CYP17 gene is asso
A polymorphism in the CYP17 gene is associated with prostate cancer risk
✍ Andrea Gsur; Gabriele Bernhofer; Sonja Hinteregger; Gerald Haidinger; Georg Scha πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 63 KB πŸ‘ 2 views

CYP17 encodes the enzyme cytochrome P-450c17␣, which mediates both 17␣-hydroxylase and 17,20-lyase in the steroid biosynthesis pathway. A polymorphism in the 5 promoter region of the CYP17 gene has been described. Steroid hormones, especially androgens, are believed to play a key role in the etiolog

Significant associations of prostate can
Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy
✍ Bo-Ying Bao; Jiunn-Bey Pao; Chun-Nung Huang; Yeong-Shiau Pu; Ta-Yuan Chang; Yu-H πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 373 KB

## Abstract Androgen‐deprivation therapy (ADT) is the most common therapy for advanced prostate cancer, but the prognosis significantly differs among individuals. In this study, we evaluated recently identified 19 prostate cancer susceptibility variants as prognostic predictors for the survival aft